VetStem regains full control of PrecisePRP after settlement with PetVivo

VetStem has ended its exclusive licensing deal with PetVivo and regained full rights to the PrecisePRP product line, trademark and inventory, effective July 24, 2026. The company says it is now seeking new distribution partners in the U.S. and abroad to expand access to the PRP product for veterinarians.

Why it matters: - VetStem now controls PrecisePRP® end to end, which gives the company direct authority over pricing, marketing and distribution. - The move could widen access to the off-the-shelf PRP product for dogs and horses if VetStem secures new partners. - The settlement also clears a dispute under the prior exclusive license and supply agreement, removing a commercial constraint on the product line.

What happened: - VetStem and PetVivo Holdings entered into a Termination and Settlement Agreement effective July 24, 2026. - The agreement resolves all outstanding matters tied to the parties’ prior Exclusive License and Supply Agreement for PrecisePRP®. - All rights tied to the PrecisePRP® platform, including the PrecisePRP™ trademark and remaining inventory, revert to VetStem. - PetVivo will pay VetStem $75,000 in settlement payments. - PetVivo will return the remaining PrecisePRP® inventory to VetStem.

The details: - VetStem says all financial obligations under the prior license arrangement have been satisfied and extinguished. - The agreement includes mutual releases for substantially all claims between the companies, subject to continuing obligations customary for this type of deal. - VetStem will directly handle customer inquiries, orders and adverse event reporting for PrecisePRP® during the transition. - PetVivo will refer direct complaints, adverse events, purchase questions and orders to VetStem for 12 months after the agreement’s effective date. - Vedco, Covetrus, MWI Animal Health and Patterson Veterinary Supply currently carry the PrecisePRP product line. - PrecisePRP® is described as an off-the-shelf, first-in-class platelet-rich plasma product for dogs and horses.

Between the lines: - The settlement gives VetStem a chance to rebuild the product’s commercial strategy without relying on PetVivo. - The search for new distribution partners suggests VetStem is trying to broaden reach beyond the current channel structure. - The 12-month referral period should reduce disruption for customers while the ownership transition is completed.

What’s next: - VetStem is evaluating and pursuing new distribution partnerships in the U.S. and globally. - The company says it expects to share more about those partnerships as they develop. - VetStem will continue managing PrecisePRP® customer support and adverse event reporting during the transition period. - Forward-looking plans remain subject to risks and uncertainties that could change results.